Shares of Shield Therapeutics plc (LON:STX – Get Free Report) traded up 18.2% during mid-day trading on Tuesday . The company traded as high as GBX 3.58 ($0.04) and last traded at GBX 3.46 ($0.04). 7,009,878 shares changed hands during mid-day trading, an increase of 146% from the average session volume of 2,846,169 shares. The stock had previously closed at GBX 2.93 ($0.04).
Shield Therapeutics Stock Performance
The company has a market capitalization of £29.08 million, a P/E ratio of -92.95 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The stock’s fifty day moving average price is GBX 2.71 and its 200-day moving average price is GBX 3.34.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Stories
- Five stocks we like better than Shield Therapeutics
- How to buy stock: A step-by-step guide for beginners
- Merck: 4 No-Brainer Reasons to Buy This Dip
- How to trade using analyst ratings
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
